Spring Bank Pharmaceuticals, Inc. (SBPH) Starts Presentation at Marcum MicroCap Conference

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. For more information, visit the company’s website at www.springbankpharma.com